The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
The Marcos administration has released P6.39 trillion, or 94.1 percent, of the P6.793-trillion national budget as
The Philippine National Police (PNP) and the US Homeland Security Investigations (HSI) are strengthening cooperation against
The (PPA will deploy 15 fully equipped emergency response vehicles to busy ports across the country
Twenty-seven families, or 92 individuals, evacuated after Ibid Creek in Barangay Biak na Bato, La Castellana,
The Philippines retained 20th place among 145 economies in the World Economic Forum’s (WEF) Global Gender